ROCKVILLE, Md., May 5, 2011 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced its first quarter financial results for the three month period ended March 26, 2011. The Company reported net income of $2.0 million, or $0.05 per share, compared to net income of $5.5 million, or $0.11 per share, for the period ended March 27, 2010.
First quarter 2011 revenue was $9.2 million reflecting $3.3 million recognized from initial payments received from GlaxoSmithKline Biologicals (GSK) associated with the PentaStaph™ sale and NicVAX® option and license agreements, $5 million for completion of the final PentaStaph milestone and $0.9 million for services provided to GSK under the PentaStaph and NicVAX agreements. Revenue for the first quarter 2010 was $13.7 million and included $4.8 million recognized from the initial PentaStaph and NicVAX payments, $8 million for achieving a PentaStaph performance milestone and $0.9 million for services provided under the PentaStaph and NicVAX agreements.
General and Administrative expenses were $1.3 million for the quarter ended March 26, 2011 compared to $1.8 million in the prior year period. This decrease reflects our ongoing efforts to reduce our expenses. Research and Development expenses were $5.3 million in the first quarter of 2011 compared to $5.9 million in 2010, representing a reduction in manufacturing-related activities for NicVAX. We expect that overall operating expenses for the balance of 2011 will approximate 2010 levels.
Net cash used in operating activities was $8.6 million for the first quarter of 2011 compared to $48.6 million of net cash provided by operating activities in the first quarter of 2010. The difference is attributed to a reduction in payments received from GSK in 2011 compared to 2010. Cash, cash equivalents and marketable securities totaled $102.5 million at March 26, 2011 compared to $110.7 million at the end of 2010. This decrease is primarily due to net cash used for operations. In April, we received the $5 million cash payment for the PentaStaph milestone that we recognized as revenue in first quarter of 2011.
The company did not repurchase any shares of common stock during the first quarter of 2011. Since inception of the stock repurchase plan in December 2007, we have repurchased a total of 19.9 million shares for a total of $87.2 million. A balance of $27.8 million remains available in the plan for future share repurchases.
"I am pleased that we successfully completed the final milestone for PentaStaph," said Dr. Raafat Fahim, President and Chief Executive Officer of Nabi Biopharmaceuticals. "Our obligations under the PentaStaph transition services agreement should conclude by the end of the second quarter of this year. Our NicVAX partnership with GSK continues to solidify and we are pleased with its progress. We continue to advance on track with the ongoing phase III NicVAX clinical trials and we look forward to final results from the first NicVAX Phase III trial later this year."
Recent and Upcoming Events
- Completed the final PentaStaph milestone and received the associated $5 million payment.
- The FDA recently approved Phoslyra, which is a new liquid formulation of PhosLo. Under an agreement with Fresenius USA Manufacturing, Inc. who owns the product, Nabi is entitled to a $5 million milestone payment upon the first commercial sale of this product and up to $65 million in royalties from incremental annual sales.
- Expect results from the first of two NicVAX Phase III trials in the second half of 2011
- Expect results from the second NicVAX Phase III trial in the first half of 2012
Financial Results Conference Call and Webcast Information
The Company will host a live webcast at 4:30 p.m. EDT today to discuss these results. The live webcast can be accessed at:
Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your browser. Remove the space if one exists. The webcast may also be accessed via the Nabi Biopharmaceuticals website at .
If you do not have Internet access, the U.S./Canada call-in number is 866-783-2140 and the international call-in number is 857-350-1599. The passcode is 57674715. An audio replay will be available for U.S./Canada callers at 888-286-8010 and for international callers at 617-801-6888. The replay passcode is 12387850. An audio replay of this call will be available through May 12, 2011. The press release and an archived version of the webcast will be available on the company's website at.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop products that target serious medical conditions in the areas of nicotine addiction and gram-positive bacterial infections. Nabi Biopharmaceuticals is currently developing NicVAX® (Nicotine Conjugate Vaccine), an innovative and proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse. The company is headquartered in Rockville, Maryland. For additional information about Nabi Biopharmaceuticals, please visit www.nabi.com
Statements in this release that are not strictly historical are forward-looking statements and include statements about products in development, results and analyses of clinical trials and studies, research and development expenses, cash expenditures, licensure applications and approvals, and alliances and partnerships, among other matters. You can identify these forward-looking statements because they involve our expectations, intentions, beliefs, plans, projections, anticipations, or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to, risks relating to our ability to conduct and obtain successful results from our two Phase III clinical trials for NicVAX; GSK's failure to exercise its option for and successfully commercialize NicVAX; GSK's failure to successfully develop and commercialize any future generation candidate nicotine vaccine; our ability to commercialize NicVAX if GSK does not exercise its option for NicVAX; our ability to raise sufficient new capital resources to fully develop and commercialize NicVAX if GSK does not exercise the NicVAX option; our ability to attract, retain and motivate key employees; our ability to collect any further milestones and royalty payments under the PhosLo agreement; the ability to obtain regulatory approval for NicVAX and any future generation candidate nicotine vaccine in the U.S. or other markets; our ability to successfully contract with contract manufacturing organizations for the manufacture and supply of NicVAX; our ability to comply with reporting and payment obligations under government rebate and pricing programs; and loss of full use of our net operating loss carry forwards. These factors are more fully discussed, as are other factors, in our Annual Report on Form 10-K for the fiscal year ended December 25, 2010 filed with the Securities and Exchange Commission.
CONTACT: Investor Relations 301-770-3099 www.nabi.com